Kiniksa Pharmaceuticals International, plc Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc

KNSA

Peringkat dalam Saham #2962
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Harga Saham
$79.61
Terakhir disinkronkan: 2026-10-19
Kapitalisasi Pasar
$6.21B
Perubahan (1 hari)
1.30%
Perubahan (1 tahun)
104.18%
Negara
GB
Perdagangan Kiniksa Pharmaceuticals International, plc (KNSA)

Kategori

Healthcare
Riwayat dividen untuk Kiniksa Pharmaceuticals International, plc (KNSA)
Saham Kiniksa Pharmaceuticals International, plc (simbol: KNSA) telah membayar total 0 dividen.
Total semua dividen (disesuaikan dengan stock split): 0.00
Imbal hasil dividen (TTM): 0
Pembayaran dividen untuk Kiniksa Pharmaceuticals International, plc (KNSA) dari 2026 hingga 2026
Pembayaran dividen tahunan
Tahun Dividen (disesuaikan dengan stock split) Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Daftar semua pembayaran dividen
Tahun Dividen Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Pembayaran dividen untuk perusahaan sejenis atau pesaing